| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 20 |
| 1 | CYCLOPHOSPHAMIDE | 15 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 15 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 15 |
| 4 | IBRUTINIB | 12 |
| 5 | DOXORUBICIN | 11 |
| 6 | CYCLOSPORINE | 10 |
| 7 | ADALIMUMAB | 9 |
| 8 | URSODIOL | 9 |
| 9 | URSOSIOL | 9 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TRIMIPRAMINE | 1 | 0.0009 |
| 1 | PIOGLITAZONE AND METFORMIN HYDROCHLORIDE | 1 | 0.0008 |
| 2 | MITOXANTRONE HYDROCHLORIDE | 4 | 0.0006 |
| 3 | BREXUCABTAGENE AUTOLEUCEL | 1 | 0.0005 |
| 4 | URSOSIOL | 9 | 0.0005 |
| 5 | CARMUSTINE | 2 | 0.0004 |
| 6 | URSODIOL | 9 | 0.0004 |
| 7 | GLOFITAMAB | 1 | 0.0004 |
| 8 | MELPHALAN HYDROCHLORIDE | 7 | 0.0003 |
| 9 | AMANTADINE HYDROCHLORIDE | 1 | 0.0002 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 20 |
| 1 | Corticosteroid [EPC] | 16 |
| 2 | Alkylating Drug [EPC] | 15 |
| 3 | Kinase Inhibitor [EPC] | 13 |
| 4 | Calcineurin Inhibitor Immunosuppressant [EPC] | 10 |
| 5 | Bile Acid [EPC] | 9 |
| 6 | Tumor Necrosis Factor Blocker [EPC] | 9 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 8 |
| 8 | Thalidomide Analog [EPC] | 8 |
| 9 | BCL-2 Inhibitor [EPC] | 7 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Bile Acid [EPC] | 9 | 0.0004 |
| 1 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 1 | 0.0002 |
| 2 | BCL-2 Inhibitor [EPC] | 7 | 0.0001 |
| 3 | Antimetabolite Immunosuppressant [EPC] | 2 | 0.0001 |
| 4 | Topoisomerase Inhibitor [EPC] | 7 | 0.0001 |
| 5 | Calcineurin Inhibitor Immunosuppressant [EPC] | 10 | 0.0001 |
| 6 | Provitamin D2 Compound [EPC] | 2 | 0.0001 |
| 7 | CD20-directed Cytolytic Antibody [EPC] | 20 | 0.0001 |
| 8 | Alkylating Drug [EPC] | 15 | 0.0001 |
| 9 | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | 1 | 0.0000 |